C&EN Global Enterprise最新文献

{"title":"On our radar","authors":"None Matt Blois, None Alex Scott","doi":"10.1021/cen-10137-cover12","DOIUrl":"https://doi.org/10.1021/cen-10137-cover12","url":null,"abstract":"Flo Materials makes endlessly recyclable plastics Shoes, carpets, and packaging are each made from several types of plastic, which makes them hard to recycle. In addition, some types of plastic start to degrade after being repeatedly recycled. The start-up Flo Materials, founded in 2021, is trying to commercialize a group of vitrimer plastics called enamine covalent adaptive networks (ECANs). These can be recycled endlessly, even if they are combined with other materials. The company, which is located in Berkeley, California, says its recycling process, based on research from Lawrence Berkeley National Laboratory , breaks down the plastic to monomers that are just as good as virgin materials. It also removes colors, contaminants, and additives. Flo CEO Kezi Cheng says that like high- performance thermosetting polymers, such as epoxy or polyurethane foam, her company’s materials are resistant to heat and chemical degradation. The bonds that make thermoset materials strong also make","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"28 22","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reactions","authors":"","doi":"10.1021/cen-10137-reactions","DOIUrl":"https://doi.org/10.1021/cen-10137-reactions","url":null,"abstract":"NUCLEAR POWER Reactions ShareShare onFacebookTwitterWechatLinked InRedditEmail C&EN, 2023, 101 (37), p 3November 13, 2023Cite this:C&EN 101, 37, 3Letters to the editorNuclear wasteA provocative editorial in every sense of the word (Sept. 18, 2023, page 2). Yes, we do have a looming disaster of our impact on the global climate, one that will remain well beyond our remaining lifetimes today. Yes, urgent action is required. However, I would like to suggest that conventional nuclear power is not the solution, or even close to it. There are several reasons. I shall stick with one, not the elephant in the room but the mastodon in the room: nuclear waste.Mitch Jacoby mentions permanent repositories. In their current form these are major environmental disasters waiting to happen. Why? The main reason is that even with the vitrification technologies of today, it is near impossible to understand the chemistry, the materials science, and the physics of these matrices in 100 years, 1,000 years, or 1 million years in the future. Evidence from Hanford and continuing efforts of its cleanup tell us much of what to expect to happen in these so-called permanent repositories.If we do go this route, they will need to remain permanently accessible for the continued reprocessing for several hundreds of thousands of years—potentially longer periods. Imagine what the person-hour rate would be in 500,000 years. Imagine how people will look back on the generation that created this waste. Of course, this assumes we do not develop technologies to deal with this waste in the future, which we well might; however, the waste still needs to be accessible. It is of course possible that this waste would undergo subduction into the mantle. A proper life-cycle analysis (ISO 144040), including the continuous waste reprocessing cycles for several thousands of years, would show it to be a very expensive energy source, indeed.Paul JonsenHarrogate, EnglandNowhere in “Can Small Modular Reactors Save Nuclear Energy?” was there a mention of how the waste from these reactors will be disposed of (Sept. 11, 2023, page 30). Maybe we should figure out what to do with the mountains of nuclear waste already created over the last 7 decades of nuclear power generation before we start generating more.Jim SchulteCicero, Illinois CorrectionsSept. 18, 2023, page 40: Newscripts has an incorrect print publication date. It was published in the Sept. 18, not Sept. 11, issue.Oct. 23, 2023, page 30: A quote in the cover story on cool-roof coatings incorrectly implies that Victoria Scarborough is affiliated with the Cool Roof Rating Council. She was instead pointing to the group as a resource.Oct. 30, 2023, page 14: A business news story about Roche’s acquisition of Telavant Holdings describes Roche incorrectly. The company is Swiss, not French.Oct. 30, 2023, page 28: The cover story on small-molecule drugs gives an incorrect affiliation for Matthew Disney. He is based at the Herbert Wertheim UF Scripps Instit","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"28 19","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EPA to rebuild endocrine disruptor program","authors":"None Britt E. Erickson","doi":"10.1021/cen-10137-polcon4","DOIUrl":"https://doi.org/10.1021/cen-10137-polcon4","url":null,"abstract":"After decades with little progress, the US Environmental Protection Agency plans to revamp an effort to evaluate pesticides for potential effects on estrogen, androgen, and thyroid hormones. The move follows a late-2022 lawsuit from environmental and farmworker groups and a scathing 2021 report from the EPA’s Office of Inspector General over endocrine disruptor testing delays. The EPA’s beleaguered Endocrine Disruptor Screening Program, created in 1998 to comply with changes to US food and drinking-water laws, has been on hiatus with no “effective internal controls in place since 2015,” according to the 2021 report. To get the program back on track, the EPA will request data from manufacturers for 30 pesticides that showed estrogen or androgen activity when agency scientists tested them with high-throughput assays and computational modeling , the agency announced Oct. 26. The 30 high-priority pesticides are part of a group of 403 pesticides that the EPA is reviewing","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"29 21","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136281522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blackrock invests in direct air capture","authors":"None Craig Bettenhausen","doi":"10.1021/cen-10137-buscon7","DOIUrl":"https://doi.org/10.1021/cen-10137-buscon7","url":null,"abstract":"The investment firm BlackRock will put $550 million into a direct-air-capture (DAC) project being developed by a subsidiary of the oil and gas giant Occidental. Under the terms of the deal, BlackRock and Oxy will form a joint venture that will own Stratos, a DAC facility that Oxy is building in Texas. When the plant comes on-line in 2025, the firms expect it to remove 500,000 metric tons of carbon dioxide per year from the ambient air. In August, Oxy bought Carbon Engineering, the DAC technology provider for the project, for $1.1 billion.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"29 6","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136281530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Almac details expansion plans","authors":"None Rick Mullin","doi":"10.1021/cen-10137-buscon17","DOIUrl":"https://doi.org/10.1021/cen-10137-buscon17","url":null,"abstract":"Almac has published details of a $98 million investment program that will expand its pharmaceutical and diagnostic service units with manufacturing and laboratory assets at its headquarters in Craigavon, Northern Ireland. Plans include a 9,300 m 2 production facility supporting oral dosage drugs and a 3,700 m 2 development center with diagnostic kit manufacturing facilities. Alma, which has set a recruitment goal of 1,000 new staffers in Northern Ireland over 3 years, says this expansion will create more than 550 jobs.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"29 23","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136281520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ashland plans restructuring","authors":"None Matt Blois","doi":"10.1021/cen-10137-buscon10","DOIUrl":"https://doi.org/10.1021/cen-10137-buscon10","url":null,"abstract":"The chemical firm Ashland is scaling back production of the food and cosmetic ingredients carboxymethyl cellulose, methyl cellulose, and hydroxyethyl cellulose in response to low demand. The company also plans to sell its nutraceuticals business. Ashland recently announced that it will focus on industries in which it has the biggest technology advantage, such as ingredients for pharmaceuticals, personal care products, and coatings. The firm sold its adhesives business to Arkema for $1.65 billion in 2022 .","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"29 16","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136281525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Septerna","authors":"None Laurel Oldach","doi":"10.1021/cen-10137-cover9","DOIUrl":"https://doi.org/10.1021/cen-10137-cover9","url":null,"abstract":"There are hundreds of G protein–coupled receptors (GPCRs) in the human genome, regulating just about every physiological system. While roughly a third of marketed drugs target a GPCR, many of the receptors have remained out of reach for drug hunters, in part because of challenges involved in studying them . After the heyday of GPCR-targeting drugs in the 1990s and early 2000s, few medicines targeting these proteins have been introduced. But new technologies may be poised to change that. A few years ago, chemistry Nobel laureate Robert J. Lefkowitz was working with scientists in his lab at Duke University in North Carolina to develop a new way to isolate enzymatically active GPCRs. Halfway around the world, at Monash University in Melbourne, Australia, the eminent pharmacology duo Patrick Sexton and Arthur Christopoulos was simultaneously developing techniques to modulate GPCR signaling using structure-based drug design. And in San Francisco, Jeffrey Finer, a","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"26 25","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Goodyear, Visolis plan biobased isoprene","authors":"None Matt Blois","doi":"10.1021/cen-10137-buscon9","DOIUrl":"https://doi.org/10.1021/cen-10137-buscon9","url":null,"abstract":"The Goodyear Tire & Rubber Company is working with the biomanufacturing firm Visolis to develop a process for producing biobased isoprene, a precursor for some types of synthetic rubber used to make tires. Isoprene is typically made as a by-product of oil refining. Visolis plans to make the chemical from lignocellulosic feedstock, which is inedible biomass. In 2007, Goodyear entered into a partnership with Genencor to produce isoprene enzymatically from plant sugars. The partners initially hoped to commercialize the product by 2013 but haven’t announced additional progress.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"28 9","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clariant to purchase Lucas Meyer Cosmetics","authors":"None Craig Bettenhausen","doi":"10.1021/cen-10137-buscon3","DOIUrl":"https://doi.org/10.1021/cen-10137-buscon3","url":null,"abstract":"Clariant has agreed to buy the personal care ingredient maker Lucas Meyer Cosmetics from International Flavors & Fragrances (IFF) for $810 million. The deal also includes another ingredient brand, IBR, as well as 195 employees and six research and production sites around the world. Clariant CEO Conrad Keijzer said on an Oct. 30 call with analysts that IFF’s cosmetic ingredient business had a profit margin of almost 50% on sales of $100 million in 2022. The firm aims to increase sales to $180 million by 2028. IFF bought Lucas Meyer in 2015 for $305 million. But after its 2021 merger with DuPont’s nutrition and biosciences business, IFF has been restructuring to focus on nutrition, scent, and health-care markets. It sold a microbial control business to Lanxess last year and two specialty flavoring units to private equity firms earlier this year . On the call, Keijzer said cosmetic ingredients are “one","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"28 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulators, researchers develop AI safeguards","authors":"None Laurel Oldach","doi":"10.1021/cen-10137-scicon1","DOIUrl":"https://doi.org/10.1021/cen-10137-scicon1","url":null,"abstract":"Artificial intelligence and machine learning tools are already being used to power voice assistants and self-driving cars, determine what users see on the internet, and guide drug design and chemical syntheses. But there are concerns about their ability to push disinformation, compromise cybersecurity, and engineer harmful biological materials. Governments around the world hope to mitigate those risks without quashing progress in the problems that AI seems poised to solve. A recent executive order by US president Joe Biden announced measures to make AI systems safer, such as requiring their developers to search for ways that bad actors could exploit the tools. Shortly after the order’s announcement , government and corporation representatives gathered in the UK for a summit on the risks of AI; 28 countries signed a declaration that supports continuing development of the technology but calls for more research into its potential risks. Many parts of the chemical enterprise","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"54 12","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136283252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}